Resource Centers
Spotlight
Business
News
Conferences
Partners
CME/CE
Subscribe
- Drug Coverage
- Hypertrophic Cardiomyopathy (HCM)
- Vaccines: 2023 Year in Review
- Eyecare
- Urothelial Carcinoma
- Women's Health
- Hemophilia
- Heart Failure
- Vaccines
- Neonatal Care
- NSCLC
- Type II Inflammation
- Substance Use Disorder
- Gene Therapy
- Lung Cancer
- Spinal Muscular Atrophy
- HIV
- Post-Acute Care
- Liver Disease
- Pulmonary Arterial Hypertension
- Safety & Recalls
- Biologics
- Asthma
- Atrial Fibrillation
- Type I Diabetes
- RSV
- COVID-19
- Cardiovascular Diseases
- Breast Cancer
- Prescription Digital Therapeutics
- Reproductive Health
- The Improving Patient Access Podcast
- Blood Cancer
- Ulcerative Colitis
- Respiratory Conditions
- Multiple Sclerosis
- Digital Health
- Population Health
- Sleep Disorders
- Biosimilars
- Plaque Psoriasis
- Leukemia and Lymphoma
- Oncology
- Pediatrics
- Urology
- Obstetrics-Gynecology & Women's Health
- Opioids
- Solid Tumors
- Autoimmune Diseases
- Dermatology
- Diabetes
- Mental Health
9 factors that drive healthcare costs
From the State Health Care Cost Containment Commission
- Physician, facility, and drug costs are high.
- Americans use a higher proportion of expensive medicine.
- Care is fragmented and uncoordinated.
- Consumers do not weigh costs when making health care decisions.
- The traditional fee-for-service payment model promotes fragmentation and higher spending.
- Administrative expenses are high.
- Unhealthy lifestyle choices and behaviors add to health burdens.
- End-of-life care in the United States is expensive.
- Provider consolidation and market power.
Source: The Miller Center, University of Virginia, prepared for the State Health Care Cost Containment Commission, January 2014
Related Videos
Related Content
DC Roundtable: Patrick Cooney of The Federal Group Drops the Latest on PBM Legislation in Washington
April 11th 2024Podcast
In this episode of "DC Roundtable," Peter Wehrwein, managing editor of Managed Healthcare Executive, spoke with Patrick Cooney, president of The Federal Group, a lobbying and strategic planning firm in Washington, D.C., about recent developments in Washington concerning PBMs.
Listen
